A Double Blinded, Placebo Controlled, Crossover Infusion Study of Respiratory Pharmacodynamics of ENA-001 in Conjunction with Propofol, Hypoxia, and Hypercapnia
Latest Information Update: 03 Jun 2024
At a glance
- Drugs ENA-001 (Primary) ; Propofol
- Indications Hypoxia; Respiration disorders
- Focus Adverse reactions; Pharmacodynamics
- Acronyms CHDR2119
- Sponsors Enalare Therapeutics
- 01 Jun 2024 Results (n=12) assessing reversal of propofol-induced depression of the hypoxic ventilatory response by BK-channel blocker published in the Anesthesiology
- 22 Aug 2023 According to a Enalare Therapeutics media release, data assessing how ENA-001 restores the bodies ventilatory control sensitivity blunted by propofol (i.e., a non-opioid central depressant) by acting on the peripheral chemoreceptors and the pharmacokinetic-pharmacodynamic modeling from this trial will be presented at the American Society of Anesthesiologists (ASA) Annual Meeting 2023.
- 28 Sep 2021 New trial record